Teva Pharmaceutical Industries Ltd (TEVA)

11.04 +0.05  +0.46% NYSE Apr 9, 20:00 USD
View Full Chart
Price Chart
View All TEVA News

News

View All Events

Events

Date Type Description
05/07/2020 08:00 EDT Earnings Calls Q1 2020 Earnings Call
05/07/2020 07:00 EDT Earnings Results Q1 2020 Earnings Results
06/09/2020 16:30 IST Agm 2019 Annual General Meeting
08/05/2020 08:00 EDT Earnings Calls Q2 2020 Earnings Call
08/05/2020 00:00 Earnings Results Q2 2020 Earnings Results
11/05/2020 07:00 EST Earnings Results Q3 2020 Earnings Results
11/05/2020 08:00 EST Earnings Calls Q3 2020 Earnings Call
02/10/2021 07:00 EST Earnings Results Q4 2020 Earnings Results
02/10/2021 08:00 EST Earnings Calls Q4 2020 Earnings Call
04/28/2021 07:00 EDT Earnings Results Q1 2021 Earnings Results
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • URL: https://www.tevapharm.com
  • Investor Relations URL: http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-irhome
  • HQ State/Province: N/A
  • Sector: Healthcare
  • Industry: Drug Manufacturers - Specialty & Generic
  • Equity Style: Mid Cap/Value
  • Next Earnings Release: Apr. 28, 2021
  • Last Earnings Release: Feb. 10, 2021
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: Nov. 27, 2017
  • Description: Headquartered in Israel, Teva Pharmaceutical is the largest generic drug manufacturer in the world. The company was formed in 1901 and has a portfolio of more than 3,500 medicines--roughly 1 out of 9 generic prescriptions in the U.S. is filled with a Teva product. The company also develops branded pharmaceuticals in the central nervous system, oncology, and respiratory categories. Teva's generic drug sales represent slightly over half of total revenue, with branded drug and distribution revenue making up the balance. Teva is an aggressive filer to bring generic drugs to market when brand patents expire and has the most generic products pending Food and Drug Administration approval.

Top Fund Holders

Symbol Name Weighting
EIS iShares MSCI Israel ETF 7.21%
PPH VanEck Vectors Pharmaceutical ETF 3.87%
BMPEX Beck, Mack & Oliver Partners 3.26%
CCM8341 IA Clarington Global Opportunities FX (USD) 2.52%
MKIEX McKee International Equity Instl 2.32%
MVISX Miller Opportunity IS 2.18%
TAM003 Thornmark Dividend & Income 1.83%
PPYPX PIMCO RAE International I-2 0.88%

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.